The Relationship between B7-H4 Expression and Clinicopathological Characteristics in Clinical Stage T1 Conventional Renal Cell Carcinoma by Jung, Suk Gun et al.
Korean Journal of Urology
Ⓒ The Korean Urological Association, 2011 90 Korean J Urol 2011;52:90-95
www.kjurology.org
DOI:10.4111/kju.2011.52.2.90
Urological Oncology
The Relationship between B7-H4 Expression and 
Clinicopathological Characteristics in Clinical Stage T1 
Conventional Renal Cell Carcinoma
Suk Gun Jung, Kyung Un Choi
1, Sang Don Lee, Zeong Zoo Lee, Moon Kee Chung
Departments of Urology and 
1Pathology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, 
Yangsan, Korea
Purpose: The diagnosis of clinically early-stage (T1) renal cell carcinoma (RCC) has 
increased. The present study evaluated the association of B7-H4 expression on the 
pathological outcome and recurrence of carcinoma in the T1 stage of RCC.
Materials and Methods: Among patients who underwent partial or radical neph-
rectomy after diagnosis of T1 stage RCC during the period of January 2000 to March 
2007, 102 pathologically confirmed cases of clear cell carcinoma were included in this 
study. The patients' medical records were reviewed retrospectively. For the im-
munohistochemical staining tests, the B7-H4 antibody (Abbiotec 1:500) was used, and 
clinicopathological characteristics were analyzed.
Results: The mean age of the patients (39 males: 38.2%, 63 females: 61.8%) was 53.0±
12.0 years (range, 31-74 years), and the mean follow-up time was 33.4±21.0 months 
(range, 6-84 months). B7-H4 expression was positive in 18 cases and negative in 84 
cases. Recurrence during the follow-up period occurred in 5 cases in the group with pos-
itive B7-H4 expression and in 7 cases in the group with negative B7-H4 expression, 
respectively (p=0.035). In the univariate analysis, a statistically significant relation-
ship was observed only for the presence of B7-H4 expression (p=0.0019). In the multi-
variate analysis, other than the expression of B7-H4, cancer size and TNM stage had 
effects on the recurrence of cancer. 
Conclusions: For clear cell RCC, B7-H4 expression had a critical impact on the prognosis 
of the patients, particularly on the recurrence of the carcinoma in patients with clinical 
stage T1 RCC.
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INTRODUCTION
The classification of patients with renal cell carcinoma 
(RCC) by the level of risk for local recurrence, prognosis, 
and survival is important for patients and clinicians to con-
sider before surgery so that appropriate treatment and fol-
low-up can be provided. Several anatomical, clinical, histo-
logical, and molecular factors have been reported as useful 
for the prediction of patient prognosis [1]. Since 2001, nu-
merous studies have been performed on a variety of clinical 
and pathological factors that can be used to determine a 
more accurate prognosis [2,3]. More recently, the assess-
ment of molecular genetic characteristics has become im-
portant for the prediction of tumor-specific survival. Many 
genes and the associated proteins have been studied for 
their association with patient prognosis [4]. For example, 
a recent study from the Mayo Clinic reported that the ex-
pression of the B7-H4 protein was detected in a diverse 
group of malignant tumors including RCC; this protein has 
been associated with blocking of antitumor mechanisms 
[5]. B7-H4 was first reported by Chen et al in 2003; it is the 
ligand of the B7 protein and a suppressor of T cell mediated Korean J Urol 2011;52:90-95
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FIG. 1. Immunohistochemical staining 
of B7-H4. (A) Negative, (B) Positive 
(H&E, x200).
immunity [6-8]. The B7-H4 protein is overexpressed in 
lung tumors, breast tumors, and ovarian tumors [9]. 
　RCC has been classified as an immunogenic tumor, with 
lymphocyte infiltration. On occasion, complete disappea-
rance of metastatic tumors, after the surgical removal of 
primary tumors, has been observed. However, only 5% to 
10% of cases of advanced RCC respond to cytokine-based 
immunotherapy [10]. The mechanism associated with the 
ability of renal cancer cells to evade antitumor immunity 
is unknown and the focus of many current studies. 
　Currently, due to the increased use of radiological diag-
nostic techniques and the interest in prevention, the clin-
ical diagnosis of early-stage RCC has increased. The goal 
of this study was to examine the association of the ex-
pression of B7-H4 with the pathological characteristics of 
RCC, patient prognosis, and disease recurrence in patients 
with stage T1 RCC.
MATERIALS AND METHODS
1. Materials
Among patients diagnosed with clinical stage T1 RCC who 
underwent a partial or radical nephrectomy from January 
2000 to March 2007, 102 patients were confirmed to have 
clear cell tumors by the postsurgical pathological evalua-
tion.
2. Clinical and pathological characteristic
Clinical and pathological characteristics were analyzed 
retrospectively on the basis of information in the patients’ 
medical records. The data collected included age at the time 
of surgery, gender, tumor size at the time of diagnosis, and 
the presence or absence of symptoms. Patients with an ab-
dominal lump, abdominal pain, macroscopic hematuria, a 
varicocele, or weight loss were considered symptomatic at 
the time of diagnosis. The histological type of tumor, TNM 
disease stage, nuclear grade, presence or absence of tumor 
necrosis, and presence or absence of lymphovascular in-
vasion were evaluated. 
　The definitions of disease progression included local re-
currence, lymph-node metastasis, and distant metastasis. 
However, in this study, no cases of local recurrence were 
identified.
3. Immunohistochemical staining
Sections 4 μm in thickness were obtained from paraffin- 
embedded tissues, attached to coated slides, incubated in 
a 60
oC oven for 1 hour, deparaffinized by repeated treatment 
with xylene for 5 minutes four times, dehydrated by several 
steps of alcohol, and washed with distilled water. For anti-
genic recovery, the slides were soaked in 0.01 M citrate buffer 
and boiled in a microwave for approximately 10 minutes. 
Afterwards, the slides were cooled at room temperature for 
30 minutes, washed with washing buffer for 3 minutes 
three times, and reacted in 3% H2O2 solution for 5 minutes 
to remove intrinsic peroxidase. The slides were washed 
with wash buffer four times, reacted with the first B7-H4 
antibody (Abbiotec 1:500, rabbit polyclonal antibody) over-
night at 4
oC, washed four times, and reacted with horserad-
ish peroxidase polymer conjugate for 10 minutes. Subse-
quently, the slides were washed with wash buffer four 
times, stained with diaminobenzidine, counterstained 
with hematoxylin, sealed, and examined under the light 
microscope. 
　The sporadic expression of B7-H4 protein in the distal 
convoluted tubules was considered the positive control 
group. Cases in which expression of the B7-H4 protein was 
detected in more than 10% of the tumor cells were consid-
ered positive, and cases in which expression was less than 
10% were considered negative [11]. The results of the stain-
ing were interpreted by one pathologist. The tumor cells 
that were stained reddish brown with B7-H4 antibody were 
read as positive (Fig. 1).
4. Statistical analysis
The results were divided into groups with and without ex-
pression of B7-H4 and clinical and pathological character-
istics were analyzed. For the analysis of recurrence-free Korean J Urol 2011;52:90-95
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TABLE 1. Clinical and pathologic features by tumor B7-H4 
expression
Variables n
B7-H4 antibody 
staining, n  (%) p-value
a
Positive Negative
Age  (yr) 0.897
　＜65 76 10 (13.2) 66 (86.8)
　≥65 26 8 (30.8) 18 (69.2)
Sex 0.577
　Male 39 13 (33.3) 26 (66.7)
　Female 63 5 (7.9) 58 (92.1)
Symptoms at 
presentation
0.461
　Absent 84 17 (20.2) 67 (79.8)
　Present 18 1 (5.6) 17 (94.4)
Primary tumor 
size  (cm)
0.239
　≤4 67 7 (10.4) 60 (89.6)
　4-7 35 11 (31.4) 24 (68.6)
Primary tumor 
classification
0.19
　pT1a 64 7 (10.9) 57 (89.1)
　pT1b 32 8 (25) 24 (75)
　pT3a   6 3 (50) 3 (50)
Nuclear grade 0.08
　1-2 82 12 (14.6) 70 (85.4)
　3-4 20 6 (30) 14 (70)
Lymphovascular 
invasion
0.949
　Absent 97 17 (17.5) 80 (82.5)
　Present   5 1 (20) 4 (80)
a: Pearson’s chi-square test
FIG. 2. Recurrence-free survival of the patients with renal cell 
carcinoma according to B7-H4 expression status (p=0.0019).
survival, univariate analysis, Kaplan-Meier, and the log- 
rank tests were performed. For the multivariate survival 
analysis, Cox's proportional hazard regression model was 
performed. The factors considered in the analysis included 
recurrence, age, gender, symptoms at the time of diagnosis, 
tumor size at the time of diagnosis, pathological disease 
stage, nuclear grade, lymphovascular invasion, and the ex-
pression of B7-H4. SPSS ver. 14.0 (SPSS Inc., Chicago, IL, 
USA) for Windows was used for the statistical analysis, and 
p-values less than 0.05 were considered statistically 
significant.
RESULTS
1. Relationship between the expression of B7-H4 and clin-
ical and pathological characteristics
The mean age of the study group was 53.0±12.0 years (range, 
31-74 years). The mean postsurgical follow-up period was 
an average of 33.4±21.0 months (range, 6-84 months). 
Males and females accounted for 39 patients (38.2%) and 
63 patients (61.8 %), respectively. The immunohistochemi-
cal staining showed that the group with expression of 
B7-H4 and the group without expression included 18 
(17.6%) and 84 patients (82.4%), respectively. In the group 
with expression of B7-H4, 8 patients had a partial neph-
rectomy, and in the group without B7-H4 expression, 57 pa-
tients had a partial nephrectomy. Only 1 patient who had 
a partial nephrectomy had positive surgical margins; how-
ever, this patient did not have disease recurrence.
　There was no significant difference between the groups 
with and without B7-H4 expression with regard to age, gen-
der, symptoms at the time of diagnosis, tumor size at the 
time of diagnosis, TNM disease stage, lymphovascular in-
vasion, or nuclear grade (Table 1). 
2. Relationship between the expression of B7-H4 and re-
currence rate
Among the 102 patients, in 5 out of 18 patients (27.8%) who 
were positive for the expression of B7-H4, lymph node 
metastasis and distant metastasis developed during the 
follow-up period. Among 84 patients negative for the ex-
pression of B7-H4, 7 patients (8.3%) developed disease re-
currence; there was a higher recurrence rate in the B7-H4- 
positive group (p=0.035). Among the factors studied for 
their association with disease recurrence, only the ex-
pression of B7-H4 showed a statistically significant rela-
tionship by univariate analysis (Fig. 2). The multivariate 
survival analysis for postsurgical disease recurrence 
showed that expression of B7-H4, tumor size, and disease 
stage were associated with disease recurrence (Table 2). 
DISCUSSION
Several types of genes, proteins, and growth factors have 
been associated with the prognosis of patients who have 
RCC [4]. One such factor, carbonic anhydrase IX (CAIX), 
is a prognostic factor that has been widely investigated. By 
controlling intra- as well as extracellular acidity, CAIX 
plays an important role in the adaptation of cells to hypoxic 
environments. According to Bui et al, CAIX was shown to 
be an independent prognostic factor for the tumor-specific 
survival rate, and regardless of the disease stage of the tu-
mors or their histological grade, the probability of death in Korean J Urol 2011;52:90-95
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TABLE 2. Relationship between various parameters and re-
currence-free survival
Variables
Univariate 
analysis
Multivariate analysis
p-value
a Hazard 
ratio
p-value
a
Age 0.289 2.607 0.106
Sex 0.457 0.491 0.484
Symptoms at presentation 0.955 0.440 0.507
Primary tumor size 0.574 5.404 0.020
Stage 0.279 3.909 0.048
Nuclear grade 0.135 0.130 0.719
Lymphovascular invasion 0.678 0.414 0.520
B7-H4 staining 0.002 7.354 0.007
a: univariate analysis was done by using the Kaplan-Meier curve 
and the log-rank test and multivariate analysis was done by using 
the Cox's proportional hazard regression model
cases with a low expression of CAIX was approximately 
three times that than in cases with a high expression [12]. 
However, in another study performed on 730 patients with 
clear cell RCC, the multivariate analysis did not confirm 
that CAIX was an independent prognostic factor [13].
　Aberrant expression of the insulin-like growth factor 
mRNA binding protein (IMP) family member IMP-3 has 
been demonstrated in several human malignancies [14]. 
The role of IMP-3 in tumorigenesis is thought to involve the 
promotion of cellular proliferation. IMP-3 expression was 
a significant independent predictor of metastasis-free and 
overall survival after multivariate adjustment. These find-
ings were validated by Hoffmann et al in a study of 716 con-
secutive patients with clear cell RCC examined for IMP-3 
expression; 88% (629 of 716) of the specimens examined 
had pathologically localized disease at the time of neph-
rectomy [15]. Among the pathologically localized tumors, 
26% (163 of 629) stained positive for IMP-3. The 5- and 
10-year progression-free survival rates were significantly 
lower in patients with IMP-3-positive tumors than in pa-
tients with IMP-3-negative tumors (51% and 41% vs. 89% 
and 82%, respectively).
　Survivin is an antiapoptotic protein that is overex-
pressed in almost all human malignancies; it is rarely de-
tected in normal tissue. Survivin is believed to inhibit both 
the intrinsic and extrinsic caspase cascades. Survivin ex-
pression has been correlated with several adverse patho-
logical features of clear cell RCC, including tumor size, nu-
clear grade, TNM classification, presence of metastatic dis-
ease, coagulative tumor necrosis, and sarcomatoid differ-
entiation [16]. Moreover, in a series reported by Parker et 
al, 312 patients with high survivin expression were twice 
as likely to die from clear cell RCC as were patients with 
low survivin expression [16].
　The B7 family plays an important role in the regulation 
of antigen-specific T cell-mediated immune reactions. The 
expression of such proteins is limited to phagocytic and 
lymphoid cells [17]. The expression of B7-H4 and B7-H1 in 
several tumors, including clear cell RCC, has been re-
ported; they have been associated with blocking effective 
anti-tumor immune mechanisms and with an increased 
risk of tumor-specific death [18]. Several studies have dem-
onstrated the expression of B7-H4 in clear cell tumors of 
the kidneys [19]; these findings were confirmed in this 
study. The results of this study showed that tumor re-
currence was more common in patients with B7-H4 ex-
pression. 
　B7-H4 has been shown to be a suppressor of the T cell- 
mediated immune response [6-8]. Several studies have re-
ported that B7-H4 acts directly on apoptotic mechanisms 
associated with tumor cells. In particular, in ovarian tu-
mors, B7-H4 has been reported to accelerate tumor formation. 
In breast tumors, the expression of B7-H4 mRNA and pro-
tein were blocked in vitro, and this was associated with the 
acceleration of apoptosis of tumor cells [20]. Therefore, B7- 
H4 appears to act by two different mechanisms. One is as 
a negative regulator of cell-mediated antitumor activity, 
and the other is by the unresponsiveness of tumor cells to 
apoptosis. B7-H4 suppresses the proliferation of CD4 and 
CD8 T cells as well as the secretion of cellular hormones. 
The receptors are thought to be the B and T lymphocyte at-
tenuator (BTLA) expressed on activated T cells [21]. These 
mechanisms enhance disease progression and tumor acti-
vity. However, studies on the mechanism of B7-H4 activity 
are in early stages, and further research is needed.
　The results of this study confirmed the expression of B7- 
H4 in clear cell RCC. Previous studies reported the spora-
dic expression of B7-H4 in the distal convoluted tubules 
[22]. However, the expression of B7-H4 in the proximal con-
voluted tubules has not been reported [23,24]. In addition, 
the expression of B7-H4 has been associated with lympho-
cyte infiltration and a poor prognosis in patients with can-
cer [25]. Moreover, in this study, the expression of B7-H4 
was shown to increase the risk of recurrence in patients 
with localized RCC. 
　Currently, the role of genetic factors and molecular 
markers has been limited in the diagnosis and manage-
ment of patients with renal cell cancer. However, in the fu-
ture, advancements in imaging technology as well as im-
munotherapy in combination with genetic studies might 
improve the treatment and management of patients with 
renal cell cancer, such as with sunitinib and sorafenib [26].
　Molecular biomarkers can assist with the diagnosis of a 
malignancy, may represent potential therapeutic targets, 
and may offer a means to monitor disease recurrence after 
treatment. Moreover, selected biomarkers may prove use-
ful when incorporated into existing risk stratification mod-
els to help clinicians more accurately counsel patients re-
garding disease prognosis. Clinically, the use of molecular 
markers has several problems. The molecular markers re-
quire immunohistochemical staining of tumor tissues. 
Biological markers that could be used on serum and urine 
samples would be more accessible for the assessment of re-
sponse to therapy as well as for tumor surveillance [27]. Korean J Urol 2011;52:90-95
94 Jung et al
　The limitations of this study include the following. This 
study was a retrospective chart review. According to pre-
vious reports [5], the expression of B7-H4 was 59.0%, and 
in this study it was 17.6%. This low expression rate is 
thought to be due to the immunohistochemical staining 
method used to assess the expression of B7-H4 in paraffin- 
embedded tissues. Many previous studies used fresh fro-
zen samples. In addition, the study subjects in this report 
represented clinical disease limited to stage T1. Further-
more, the sample size was relatively small. 
CONCLUSIONS
The results of this study showed that the expression of 
B7-H4 was associated with the prognosis of patients with 
clear cell RCC and recurrence in patients with stage T1 
tumors. Although multiple current prognostic models 
based on clinical and pathological variables exist, further 
improvements in the accuracy of such models may be ach-
ieved with the development and implementation of molec-
ular biomarkers. The expression of B7-H4 might be used 
to manage patients with RCC and as a target for novel 
treatments.
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